Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.
Latest shares articles
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
13:36, 8 July 2024
Infosys shareholders: Who owns the most INFY stock?
Who are the major shareholders and decision-makers of Infosys?
07:12, 29 April 2024
Tesla shareholders: Who owns the most TSLA stock?
In this guide to Tesla’s ownership structure, we look at the biggest TSLA shareholders – both institutional and individual
08:00, 19 April 2024
US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co
The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.
14:43, 2 February 2024
Ratings and Reviews
Ratings and Reviews
